|By Business Wire||
|July 28, 2014 07:00 AM EDT||
Emulate, Inc. today announced the company’s launch with a $12 million Series A financing to commercialize a first-in-kind, automated ‘Organs-on-Chips’ platform that mimics human physiology and diseases, while permitting real-time elucidation of molecular mechanisms of action and toxicity. Emulate’s proprietary Organs-on-Chips platform achieves a new industry standard by predicting human responses to medicines, chemicals, and toxins more rapidly and with greater fidelity than animal models. The company’s mission is to commercialize its Organs-on-Chips bioemulation products, automated platform and software to enhance innovation and accelerate the development of pharmaceutical, chemical, cosmetic, and personalized medicine products.
The Emulate, Inc. Lung-on-Chip in the photo is lined with human lung and blood vessel cells to create a new living technology platform to emulate human biology (Photo: Business Wire)
“Emulate’s Organs-on-Chips platform provides, for the first time, a window into the inner-workings of human organs without having to invade a living body,” said James Coon, Chief Executive Officer of Emulate. “Our unique automated Organs-on-Chips approach to human bioemulation opens up entirely new possibilities to develop products with enhanced properties, improved efficacy and safety, and personalization to patients and consumers. The company will focus on key strengths of integrating design, biology and engineering to create revolutionary products. We are launching Emulate to be a leader in advancing innovative product design across multiple industries including drug development, healthcare, agriculture and consumer health.”
Emulate will use the proceeds from the financing to advance the first commercial applications of its automated Organs-on-Chips platform through co-innovation with corporate and clinical clients, and through internal development programs. The company’s initial focus will be use of Organs-on-Chips to provide more rapid and accurate evaluation of human responses to drugs and cosmetics, and to create new clinical guidance tools for personalized therapies. The Series A financing was led by the venture capital firm NanoDimension, alongside of investment by Cedars-Sinai Medical Center and private investor Hansjörg Wyss.
“Emulate’s platform has significant potential to advance human health today, not only to better design and evaluate new breakthrough medicines, but also to drive more personalized diagnosis and treatment approaches,” said Shlomo Melmed, M.D., Senior Vice President for Academic Affairs and Dean of the Medical Faculty at Cedars-Sinai. “Our vision is we can one day put each patient’s cells on chips that mimic the function of organs, and this will open up new ways for us to design truly personalized treatment with stem cells, based on each patient’s unique genetic profile on their own individualized Organs-on-Chips.”
Leading Foundational Science and Team
The company’s founding team carried out their ground-breaking foundational research, engineering and technology translation at the Wyss Institute for Biologically Inspired Engineering at Harvard University, which has made automated human Organs-on-Chips a reality. The company’s scientific founder and a pioneer in the field of organs-on-chips, Donald Ingber, M.D., Ph.D., Founding Director of the Wyss Institute and faculty member at Harvard Medical School, Harvard School of Engineering and Applied Sciences, and Boston Children’s Hospital will chair Emulate’s Scientific Advisory board. Lead Senior Staff Scientist at the Wyss Institute, Geraldine A. Hamilton, Ph.D., will join as President and Chief Scientific Officer of Emulate. James Coon, Entrepreneur-in-Residence at the Wyss Institute, has been appointed Emulate’s Chief Executive Officer. Hamilton and Coon collectively have over 30 years of experience in biotechnology startups and the pharmaceutical industry.
Emulate has a worldwide license to a robust and broad intellectual property portfolio for its bioemulation Organs-on-Chips platform from Harvard University, and is uniquely positioned to advance the technology into successful commercial applications, supported by multiple years of vigorous research and development by its experienced team of scientists and engineers.
“This advanced technology is the beginning of a revolution in the way we study human biology and disease, as Emulate sets a new standard for products to be aligned with a complete picture of human biology,” said Geraldine A. Hamilton, Ph.D. “Emulate’s Organs-on-Chips allow living human cells to interact with other cell types within the authentic physical context of living tissues and organs as they would normally in the human body. This ability to bioemulate the human organ microenvironment through microengineering – combined with automated instrumentation that permits molecular scale analysis in real-time – allows us to replicate, analyze and predict human responses in a truly unique and powerful way.”
Organs-on-Chips for Human Bioemulation
Emulate’s technology represent a unique human bioemulation platform that permits analysis of molecular functions within human cells living in an engineered microenvironment that accurately recapitulates human organ biology. Human Organs-on-Chips are miniaturized devices created with microchip manufacturing that contain tiny hollow channels lined by living human cells and tissues cultured under continuous fluid flow and mechanical forcing regimens, such as cyclic breathing and peristalsis, which effectively recapitulate organ-level physiology and disease responses. In Emulate’s automated platform, different Organs-on-Chips, such as lung, liver, intestine, kidney, skin, eye, and blood-brain-barrier, can be linked together by flowing liquid containing living human immune cells that simulates blood to form a “Human-Body-on-Chips” to more closely replicate whole body-level responses.
Emulate, Inc. is a private company focused on commercializing Organs-on-Chips as an automated human bioemulation platform that achieves a new standard for mimicking true human physiology so that responses to medicines, chemicals and diseases can be accurately predicted. Through co-innovation with collaborators and internal programs, Emulate is advancing product innovation, design and safety across a range of applications in drug development, personalized medicine, agriculture and chemical-based consumer products. For more information, visit www.emulatebio.com.
NanoDimension is a U.S. and Europe based venture capital firm specializing in nanotechnology. Founded in 2002, NanoDimension invests in early-stage companies that are developing break-through technologies at the nano-scale to disrupt markets and to solve critical global problems. For more information, visit www.nanodimension.com.
SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. For 20 years, HPM Networks has been integrating technology solutions that solve complex business challenges. HPM Networks has designed solutions for both SMB and enterprise customers throughout the San Francisco Bay Area.
Aug. 3, 2015 06:45 PM EDT Reads: 532
Learn how you can use the CoSN SEND II Decision Tree for Education Technology to make sure that your K–12 technology initiatives create a more engaging learning experience that empowers students, teachers, and administrators alike.
Aug. 3, 2015 05:45 PM EDT
In a recent research, analyst firm IDC found that the average cost of a critical application failure is $500,000 to $1 million per hour and the average total cost of unplanned application downtime is $1.25 billion to $2.5 billion per year for Fortune 1000 companies. In addition to the findings on the cost of the downtime, the research also highlighted best practices for development, testing, application support, infrastructure, and operations teams.
Aug. 3, 2015 04:30 PM EDT Reads: 211
Container technology is sending shock waves through the world of cloud computing. Heralded as the 'next big thing,' containers provide software owners a consistent way to package their software and dependencies while infrastructure operators benefit from a standard way to deploy and run them. Containers present new challenges for tracking usage due to their dynamic nature. They can also be deployed to bare metal, virtual machines and various cloud platforms. How do software owners track the usag...
Aug. 3, 2015 04:00 PM EDT Reads: 275
As Marc Andreessen says software is eating the world. Everything is rapidly moving toward being software-defined – from our phones and cars through our washing machines to the datacenter. However, there are larger challenges when implementing software defined on a larger scale - when building software defined infrastructure. In his session at 16th Cloud Expo, Boyan Ivanov, CEO of StorPool, provided some practical insights on what, how and why when implementing "software-defined" in the datacent...
Aug. 3, 2015 03:45 PM EDT
Mobile, social, Big Data, and cloud have fundamentally changed the way we live. “Anytime, anywhere” access to data and information is no longer a luxury; it’s a requirement, in both our personal and professional lives. For IT organizations, this means pressure has never been greater to deliver meaningful services to the business and customers.
Aug. 3, 2015 03:30 PM EDT Reads: 236
As organizations shift towards IT-as-a-service models, the need for managing and protecting data residing across physical, virtual, and now cloud environments grows with it. CommVault can ensure protection and E-Discovery of your data – whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise. In his session at 17th Cloud Expo, Randy De Meno, Chief Technologist - Windows Products and Microsoft Partnerships at Com...
Aug. 3, 2015 03:30 PM EDT
SYS-CON Events announced today that VividCortex, the monitoring solution for the modern data system, will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. The database is the heart of most applications, but it’s also the part that’s hardest to scale, monitor, and optimize even as it’s growing 50% year over year. VividCortex is the first unified suite of database monitoring tools specifically desi...
Aug. 3, 2015 03:15 PM EDT
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin,...
Aug. 3, 2015 03:00 PM EDT Reads: 560
In their session at 17th Cloud Expo, Hal Schwartz, CEO of Secure Infrastructure & Services (SIAS), and Chuck Paolillo, CTO of Secure Infrastructure & Services (SIAS), provide a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. In his role as CEO of Secure Infrastructure & Services (SIAS), Hal Schwartz provides leadership and direction for the company.
Aug. 3, 2015 12:30 PM EDT Reads: 208
SYS-CON Events announced today that MobiDev, a software development company, will exhibit at the 17th International Cloud Expo®, which will take place November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software development company with representative offices in Atlanta (US), Sheffield (UK) and Würzburg (Germany); and development centers in Ukraine. Since 2009 it has grown from a small group of passionate engineers and business managers to a full-scale mobi...
Aug. 3, 2015 09:45 AM EDT Reads: 367
There are many considerations when moving applications from on-premise to cloud. It is critical to understand the benefits and also challenges of this migration. A successful migration will result in lower Total Cost of Ownership, yet offer the same or higher level of robustness. In his session at 15th Cloud Expo, Michael Meiner, an Engineering Director at Oracle, Corporation, analyzed a range of cloud offerings (IaaS, PaaS, SaaS) and discussed the benefits/challenges of migrating to each offe...
Aug. 3, 2015 07:30 AM EDT Reads: 192
"We've just seen a huge influx of new partners coming into our ecosystem, and partners building unique offerings on top of our API set," explained Seth Bostock, Chief Executive Officer at IndependenceIT, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
Aug. 2, 2015 10:00 PM EDT Reads: 685
Digital Transformation is the ultimate goal of cloud computing and related initiatives. The phrase is certainly not a precise one, and as subject to hand-waving and distortion as any high-falutin' terminology in the world of information technology. Yet it is an excellent choice of words to describe what enterprise IT—and by extension, organizations in general—should be working to achieve. Digital Transformation means: handling all the data types being found and created in the organizat...
Aug. 2, 2015 06:00 PM EDT Reads: 1,138
Chuck Piluso presented a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. Prior to Secure Infrastructure and Services, Mr. Piluso founded North American Telecommunication Corporation, a facilities-based Competitive Local Exchange Carrier licensed by the Public Service Commission in 10 states, serving as the company's chairman and president from 1997 to 2000. Between 1990 and 1997, Mr. Piluso served as chairman & founder of International Te...
Aug. 2, 2015 04:00 PM EDT Reads: 434